Skip to content
Open access

One Scaffold, Many Targets: Fully Modified RNA Nanostructures for Multi-Gene Silencing Beyond the Liver

Oct 2026 · bioRxiv · 0 citations · 40 references
Biology

Abstract

Therapeutic siRNAs are a major clinical modality for hepatic gene silencing, but efficient extrahepatic delivery and multi-gene modulation remain significant barriers. Nucleic acid nanotechnology offers programmable assembly, but conventional structures suffer from enzymatic instability in vivo. Here we report fully chemically modified RNA nanostructures (FMRNs)—a vehicle-free platform entirely composed of stabilized therapeutic nucleic acids that integrate structural precision with metabolic durability. Following systemic administration, FMRNs exhibit enhanced pharmacokinetics and extrahepatic accumulation, with in vivo behavior influenced greatly by hydrodynamic size rather than molecular weight. Using triangular and square geometries, we demonstrate programmable control over siRNA stoichiometry to achieve sustained, simultaneous silencing of up to four genes from a single entity. Nanostructure assembly alone drives productive delivery, especially to heart and muscle, matching lipophilic conjugation. Furthermore, cerebrospinal fluid administration reveals that larger FMRNs improve central nervous system distribution and retention revealing physicochemical parameters that impact brain exposure. FMRNs establish a modular and effective platform combining improved pharmacokinetics, extrahepatic delivery, and multi-gene silencing for complex diseases.

Read PDF

Similar papers

#gene editing Review Open access Sep 2026

Nanocarrier-Mediated Gene Editing for Improved Tumour Therapeutic Efficacy

This paper reviews considerable recent preclinical literature to systematically summarize the classification, physicochemical properties, and diverse fabrication techniques of mainstream lipid, polymeric, and inorganic nanocarriers and provides reliable systematic theoretical support for the subsequent clinical transla...

Zi-Xin Shen · 0 citations
Sep 2026

Targeted Delivery of RNA-based Therapeutics by Lipid Nanoparticles.

Lipid Nanoparticles (LNPs) have emerged as adaptable and effective delivery systems for RNA-based therapies, transforming contemporary medicine. This article covers the design, processes, and therapeutic potential of LNPs for RNA delivery. LNPs improve RNA encapsulation, stability, and targeted cellular delivery. Lipid...

Shayeri Chatterjee Ganguly, Priya Manna, Satadeep Bandyapadhyay et al. · 0 citations
Open access

Lipid Nanoparticle-Mediated Delivery of CRISPR-Cas9 Components for Genome Editing.

This protocol describes a standardized microfluidic workflow for reproducible LNP formulation, providing practical guidance on lipid preparation, nanoparticle assembly, and quality control.

A. Olsen, C. Brandt, Rasmus Karred Larsen et al. · 0 citations
Review Sep 2026

Engineering extracellular vesicles for targeted siRNA delivery: Advances, therapeutic applications, and clinical translation.

Small interfering RNA (siRNA) therapeutics have emerged as a transformative approach for sequence-specific gene silencing, offering the potential to treat a broad spectrum of diseases by selectively suppressing disease-associated genes. However, the clinical translation of siRNA remains limited by rapid enzymatic degra...

G. S. Amrish Varshan, S. Namasivayam · 0 citations
#gene editing Open access Oct 2026

Delivering the Undeliverable: Rational Engineering of Membrane-Based and Synthetic Nanoparticle Platforms

Delivering therapeutic macromolecules to defined cell populations in vivo remains a central unsolved problem in biomedicine. Proteins, nucleic acids and viral vectors are cleared by phagocytes, degraded by enzymes, blocked by endothelial and interstitial barriers, and trapped in acidifying endolysosomes. Pre-existing i...

Qiang-Bing Yang · 0 citations
Review Open access Oct 2026

Mechanisms and determinants of mRNA Lipid Nanoparticle biodistribution: From pharmacokinetics to clinical translation

Abstract Messenger RNA (mRNA) therapeutics formulated in lipid nanoparticles (LNPs) have transformed the field of nucleic acid medicine by enabling transient, programmable protein expression for vaccination, protein replacement, immunotherapy, and genome engineering. Extending their clinical success beyond vaccines req...

Z. Alhareth, C. López-Camacho · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.